Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

Elias Jabbour, Hagop M. Kantarjian, Giuseppe Saglio, Juan Luis Steegmann, Neil P. Shah, Concepción Boqué, Charles Chuah, Carolina Pavlovsky, Jiří Mayer, Jorge Cortes, Michele Baccarani, Dong Wook Kim, M. Brigid Bradley-Garelik, Hesham Mohamed, Mark Wildgust, Andreas Hochhaus

Research output: Contribution to journalArticle

Abstract

This analysis explores the impact of early cytogenetic and molecular responses on the outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase 3 DASatinib versus Imatinib Study In treatment-Naive CML patients trial with a minimum follow-up of 3 years. Patients with newly diagnosed CML-CP were randomized to receive 100 mg dasatinib (n = 259) or 400 mg imatinib (n = 260) once daily. The retrospective landmark analysis included patients evaluable at the relevant time point (3, 6, or 12 months). Median time to complete cytogenetic response was 3 vs 6 months with dasatinib vs imatinib. At 3 and 6 months, the proportion of patients with BCR-ABL transcript levels ≤10% was higher in the dasatinib arm. Deeper responses at 3, 6, and 12 months were observed in a higher proportion of patients on dasatinib therapy and were associated with better 3-year progression-free survival and overall survival in both arms. First-line dasatinib resulted in faster and deeper responses compared with imatinib. The achievement of an early molecular response was predictive of improved progression-free survival and overall survival, supporting new milestones for optimal response in patients with early CML-CP treated with tyrosine kinase inhibitors. This study was registered at www.clinicaltrials.gov as NCT00481247.

Original languageEnglish (US)
Pages (from-to)494-500
Number of pages7
JournalBlood
Volume123
Issue number4
DOIs
StatePublished - Jan 23 2014
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic Phase
Cytogenetics
Disease-Free Survival
Emitter coupled logic circuits
Survival
Protein-Tyrosine Kinases
Imatinib Mesylate
Dasatinib
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Jabbour, E., Kantarjian, H. M., Saglio, G., Steegmann, J. L., Shah, N. P., Boqué, C., ... Hochhaus, A. (2014). Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood, 123(4), 494-500. https://doi.org/10.1182/blood-2013-06-511592

Early response with dasatinib or imatinib in chronic myeloid leukemia : 3-year follow-up from a randomized phase 3 trial (DASISION). / Jabbour, Elias; Kantarjian, Hagop M.; Saglio, Giuseppe; Steegmann, Juan Luis; Shah, Neil P.; Boqué, Concepción; Chuah, Charles; Pavlovsky, Carolina; Mayer, Jiří; Cortes, Jorge; Baccarani, Michele; Kim, Dong Wook; Bradley-Garelik, M. Brigid; Mohamed, Hesham; Wildgust, Mark; Hochhaus, Andreas.

In: Blood, Vol. 123, No. 4, 23.01.2014, p. 494-500.

Research output: Contribution to journalArticle

Jabbour, E, Kantarjian, HM, Saglio, G, Steegmann, JL, Shah, NP, Boqué, C, Chuah, C, Pavlovsky, C, Mayer, J, Cortes, J, Baccarani, M, Kim, DW, Bradley-Garelik, MB, Mohamed, H, Wildgust, M & Hochhaus, A 2014, 'Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)', Blood, vol. 123, no. 4, pp. 494-500. https://doi.org/10.1182/blood-2013-06-511592
Jabbour, Elias ; Kantarjian, Hagop M. ; Saglio, Giuseppe ; Steegmann, Juan Luis ; Shah, Neil P. ; Boqué, Concepción ; Chuah, Charles ; Pavlovsky, Carolina ; Mayer, Jiří ; Cortes, Jorge ; Baccarani, Michele ; Kim, Dong Wook ; Bradley-Garelik, M. Brigid ; Mohamed, Hesham ; Wildgust, Mark ; Hochhaus, Andreas. / Early response with dasatinib or imatinib in chronic myeloid leukemia : 3-year follow-up from a randomized phase 3 trial (DASISION). In: Blood. 2014 ; Vol. 123, No. 4. pp. 494-500.
@article{21ee73f57abc465cb9fe9342e204fb8a,
title = "Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)",
abstract = "This analysis explores the impact of early cytogenetic and molecular responses on the outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase 3 DASatinib versus Imatinib Study In treatment-Naive CML patients trial with a minimum follow-up of 3 years. Patients with newly diagnosed CML-CP were randomized to receive 100 mg dasatinib (n = 259) or 400 mg imatinib (n = 260) once daily. The retrospective landmark analysis included patients evaluable at the relevant time point (3, 6, or 12 months). Median time to complete cytogenetic response was 3 vs 6 months with dasatinib vs imatinib. At 3 and 6 months, the proportion of patients with BCR-ABL transcript levels ≤10{\%} was higher in the dasatinib arm. Deeper responses at 3, 6, and 12 months were observed in a higher proportion of patients on dasatinib therapy and were associated with better 3-year progression-free survival and overall survival in both arms. First-line dasatinib resulted in faster and deeper responses compared with imatinib. The achievement of an early molecular response was predictive of improved progression-free survival and overall survival, supporting new milestones for optimal response in patients with early CML-CP treated with tyrosine kinase inhibitors. This study was registered at www.clinicaltrials.gov as NCT00481247.",
author = "Elias Jabbour and Kantarjian, {Hagop M.} and Giuseppe Saglio and Steegmann, {Juan Luis} and Shah, {Neil P.} and Concepci{\'o}n Boqu{\'e} and Charles Chuah and Carolina Pavlovsky and Jiř{\'i} Mayer and Jorge Cortes and Michele Baccarani and Kim, {Dong Wook} and Bradley-Garelik, {M. Brigid} and Hesham Mohamed and Mark Wildgust and Andreas Hochhaus",
year = "2014",
month = "1",
day = "23",
doi = "10.1182/blood-2013-06-511592",
language = "English (US)",
volume = "123",
pages = "494--500",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Early response with dasatinib or imatinib in chronic myeloid leukemia

T2 - 3-year follow-up from a randomized phase 3 trial (DASISION)

AU - Jabbour, Elias

AU - Kantarjian, Hagop M.

AU - Saglio, Giuseppe

AU - Steegmann, Juan Luis

AU - Shah, Neil P.

AU - Boqué, Concepción

AU - Chuah, Charles

AU - Pavlovsky, Carolina

AU - Mayer, Jiří

AU - Cortes, Jorge

AU - Baccarani, Michele

AU - Kim, Dong Wook

AU - Bradley-Garelik, M. Brigid

AU - Mohamed, Hesham

AU - Wildgust, Mark

AU - Hochhaus, Andreas

PY - 2014/1/23

Y1 - 2014/1/23

N2 - This analysis explores the impact of early cytogenetic and molecular responses on the outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase 3 DASatinib versus Imatinib Study In treatment-Naive CML patients trial with a minimum follow-up of 3 years. Patients with newly diagnosed CML-CP were randomized to receive 100 mg dasatinib (n = 259) or 400 mg imatinib (n = 260) once daily. The retrospective landmark analysis included patients evaluable at the relevant time point (3, 6, or 12 months). Median time to complete cytogenetic response was 3 vs 6 months with dasatinib vs imatinib. At 3 and 6 months, the proportion of patients with BCR-ABL transcript levels ≤10% was higher in the dasatinib arm. Deeper responses at 3, 6, and 12 months were observed in a higher proportion of patients on dasatinib therapy and were associated with better 3-year progression-free survival and overall survival in both arms. First-line dasatinib resulted in faster and deeper responses compared with imatinib. The achievement of an early molecular response was predictive of improved progression-free survival and overall survival, supporting new milestones for optimal response in patients with early CML-CP treated with tyrosine kinase inhibitors. This study was registered at www.clinicaltrials.gov as NCT00481247.

AB - This analysis explores the impact of early cytogenetic and molecular responses on the outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase 3 DASatinib versus Imatinib Study In treatment-Naive CML patients trial with a minimum follow-up of 3 years. Patients with newly diagnosed CML-CP were randomized to receive 100 mg dasatinib (n = 259) or 400 mg imatinib (n = 260) once daily. The retrospective landmark analysis included patients evaluable at the relevant time point (3, 6, or 12 months). Median time to complete cytogenetic response was 3 vs 6 months with dasatinib vs imatinib. At 3 and 6 months, the proportion of patients with BCR-ABL transcript levels ≤10% was higher in the dasatinib arm. Deeper responses at 3, 6, and 12 months were observed in a higher proportion of patients on dasatinib therapy and were associated with better 3-year progression-free survival and overall survival in both arms. First-line dasatinib resulted in faster and deeper responses compared with imatinib. The achievement of an early molecular response was predictive of improved progression-free survival and overall survival, supporting new milestones for optimal response in patients with early CML-CP treated with tyrosine kinase inhibitors. This study was registered at www.clinicaltrials.gov as NCT00481247.

UR - http://www.scopus.com/inward/record.url?scp=84893136765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893136765&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-06-511592

DO - 10.1182/blood-2013-06-511592

M3 - Article

C2 - 24311723

AN - SCOPUS:84893136765

VL - 123

SP - 494

EP - 500

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -